MagForce Nanotechnologies AG (Entry Standard segment of the Frankfurt Stock
Exchange, ticker MF6), the Berlin-based medical technology company majority
owned by Nanostart AG,
has announced the appointment of Dr. Peter Heinrich as its new chief executive
officer effective January 1, 2010. Dr. Heinrich, who is a renowned executive
within the life sciences business in Germany and a leading figure in the European
biotechnology world, has served until now as deputy chairman of the supervisory
board of MagForce. Until the middle of this year, he was CEO of MediGene AG,
a biotechnology company listed on the Frankfurt Stock Exchange and included
in the TecDax index.
Dr. Heinrich will succeed outgoing chief executive Dr. Uwe Maschek, who has
resigned at his own request as of the end of the year. Professor Wolfgang M.
Heckl is rejoining the supervisory board, taking the place of Dr. Heinrich.
Professor Heckl, who is regarded as Germany’s leading nanotechnology expert,
teaches at the Technical University of Munich (TU München) and is general
director of Germany’s largest science museum, Munich’s renowned
Deutsches Museum. He also serves as deputy chairman of the supervisory board
of Nanostart AG.
“With the appointment of Peter Heinrich, we’ve been able to bring
on board a highly experienced and internationally recognized business executive,”
said Marco Beckmann, CEO of Nanostart AG. “We are confident that Dr. Heinrich
will do a superb job in leading our portfolio company MagForce through this
critical phase. We extend our sincere thanks to Dr. Maschek, the CEO until now,
for his many contributions and look forward with great enthusiasm to working
together with Dr. Heinrich. His experience and expertise make him the ideal
candidate to drive forward with the marketing and further development of Nano-Cancer®
therapy, for the benefit of cancer patients as well as the company and its shareholders.”
Dr. Heinrich added that “with its Nano-Cancer® therapy, MagForce
possesses an extremely innovative and effective therapeutic procedure for treating
solid tumors. Following the successful results of clinical trials in patients
with glioblastoma, a malignant and particularly aggressive type of brain tumor,
an application for EU-wide regulatory approval has been submitted for this first
medical indication. The next step is to drive forward vigorously with preparations
for the commercialization phase and to rapidly expand the scope of application
of our Nano-Cancer® therapy to encompass other medical indications, as well
as to position our company in the international market. It is my declared objective
to generate significant value for patients as well as for shareholders in the
Over his entire career as a pharmaceutical executive, Dr. Heinrich has been
able to produce a superb track record of successful achievements. He was co-founder
of MediGene AG, the exchange-listed biotechnology company, and served as its
managing director and CEO from 1995 until the middle of 2009, over this time
the company focused on the development of pharmaceuticals in the fields of oncology,
immunology and cardiology. There he held board-level responsibility for all
areas until the company’s stock exchange listing in 2000, after which
time he was responsible for the areas of administration, business development,
controlling, corporate finance, investor and public relations, organizational
development, intellectual property and human resources, as well as for the company’s
facilities in San Diego (California) and Oxford (UK).
With strategic far-sightedness, scientific rigor and business know-how, he
built up MediGene from a venture capital-financed start-up to an established
international biopharmaceutical company with pharmaceutical products successfully
brought to market and further candidates now in the development pipeline.
During his career at MediGene, Dr. Heinrich played a key role in achieving
a number of noteworthy milestones in the company’s development, including
the regulatory approval of the drugs Eligard®, Veregen® and Oracea®,
the acquisition of companies, the licensing in and licensing out of product
candidates, strategic partnerships with pharmaceutical corporations, and the
company’s listing on the Frankfurt Stock Exchange in 2000 as well as follow-on
capital market transactions.
Before founding MediGene, Heinrich held various positions over eight years
at Wacker Chemie AG in Munich. During this time he was substantially involved
in the development of biotechnology products which have since been successfully
brought to market.
Dr. Heinrich studied biology and chemistry at the University of Munich, and
after receiving his doctoral degree there in biochemistry, he continued with
post-doctoral work at Harvard University. He is co-founder and chairman of the
executive board of BIO-Deutschland, an independent organization representing
the interests of the German biotechnology industry. From 2001 to 2009 he served
as a member of European Biopharmaceutical Enterprises (EBE), including as its
president from 2003 to 2006. Dr. Heinrich also serves on the board of trustees
of Bayern Innovativ GmbH, as a mentor and tutor at the Bavarian Elite Academy,
and on the supervisory board of the University of Augsburg’s MBA program.